Načítá se...
Targeting acute myeloid leukemia with TP53-independent vosaroxin
Vosaroxin is a quinolone compound that intercalates DNA and induces TP53-independent apoptosis, demonstrating activity against acute myeloid leukemia (AML) in Phase I–III trials. Here, we examine vosaroxin’s mechanism of action and pharmacology, and we review its use in AML to date, focusing on deta...
Uloženo v:
| Vydáno v: | Future Oncol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Future Medicine Ltd
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5144553/ https://ncbi.nlm.nih.gov/pubmed/27615555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2016-0300 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|